The stock will trade on pipeline catalysts (BEST1 data in September, LCA5 dosing start) rather than near-term financials. The Oberland financing removes near-term dilution risk but adds $35M in senior secured debt. Watch for the June 16 R&D Science Forum for early-stage program updates and the September BEST1 readout as key binary events.
Price Chart
Executive Summary
Opus Genetics reported Q1 2026 revenue of $2.2M (down 51% YoY from $4.4M) and a GAAP net loss of $65.5M ($-0.75/share), driven by a $51.4M non-cash fair value change in warrant liabilities. The operating loss widened to $14.4M from $9.9M a year ago. Pipeline progress (BEST1 Cohort 1 data expected September 2026, LCA5 RDEP acceptance) and a $35M Oberland debt facility extending cash runway into 2029 are positive, but the core financial trajectory shows escalating operating losses and no product revenue.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $2.2M vs $4.4M YoY (-51%), all from Viatris collaboration reimbursement
- GAAP net loss $65.5M ($-0.75/share) vs $8.2M ($-0.24/share) YoY, primarily due to $51.4M non-cash warrant liability fair value charge
- Operating loss widened to $14.4M from $9.9M YoY as R&D spend increased 33% to $10.6M
- Cash $60M at quarter end; subsequent $35M Oberland senior secured notes + $5M equity commitment extends runway into 2029
- BEST1 Phase 1/2 Cohort 1 enrollment complete; three-month topline data expected September 2026
- LCA5 program accepted into FDA RDEP program; pivotal Phase 3 run-in ongoing with dosing expected Q4 2026
- RDH12 expected to enter clinic Q4 2026; MERTK clinical activities underway; RHO expected 2027
Financial Impact
Revenue decline of $2.2M (-51% YoY); operating loss increased $4.5M; net loss increased $57.3M primarily from non-cash warrant revaluation
Risk Factors
- Operating losses are accelerating with no product revenue on the horizon
- Warrant liability revaluation creates significant GAAP earnings volatility
- BEST1 and LCA5 clinical data readouts are binary events with high failure risk typical of gene therapy
- Senior secured debt from Oberland adds leverage and covenants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033856 |
| Document: ird-20260512.htm | 0001628280-26-033856 |
| Document: 0001628280-26-033856-index-headers.html | 0001628280-26-033856 |
| Document: 0001628280-26-033856-index.html | 0001628280-26-033856 |
| Document: 0001628280-26-033856.txt | 0001628280-26-033856 |
| 8-K Data (Synthetic) | 0001628280-26-033856 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 144 | $3.52 | awaiting T+60 | — | $3.32 (−5.68%) |
Oct 21, 2026 5d ago | 8-K | $3.82 | awaiting T+60 | — | $3.32 (−13.09%) |
Oct 15, 2026 11d ago | 8-K | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Oct 15, 2026 11d ago | Press Release | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.32 (−35.66%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.32 (−45.03%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.32 (−42.06%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.32 (−25.39%) |
Aug 6, 2026 11w ago | 8-K | $3.72 | awaiting T+60 | — | $3.32 (−10.75%) |
Jul 23, 2026 13w ago | 144 | $2.92 $4.05 | ▲ +38.70% | ▲ +34.15% | $3.32 (+13.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers